Key result
Time-resolved FRET assays demonstrated that PKA phosphorylation reduces cMyBP-C binding to myosin and actin, and identified unique binding alterations caused by hypertrophic cardiomyopathy mutations.
Why the study?
Efforts to elucidate the molecular interactions of cMyBP-C with myosin and actin have been limited by low-throughput, labor-intensive standard techniques.
Population
Interactions of cardiac myosin and F-actin with N-terminal cMyBP-C domains C0-C2
Comparison
Phosphorylation and HCM mutations (T59A, R282W, E334K, L349R) vs unphosphorylated wild-type
Design
In vitro time-resolved fluorescence resonance energy transfer (TR-FRET) spectroscopic assay study
Authors
Loading...
Does not support clinical changes in HCM; hypothesis-generating for mutation-specific targeting in animal models.
TR-FRET assays reveal that phosphorylation reduces cMyBP-C binding to myosin and actin, while HCM mutations uniquely alter these interactions, providing a high-throughput screening method for therapeutic discovery.
Wong et al. (2022) studied Hypertrophic cardiomyopathy (in vitro models). PKA phosphorylation and HCM mutations in cMyBP-C vs. Unphosphorylated wild-type cMyBP-C was evaluated on Binding interaction (FRET efficiency) between cMyBP-C and myosin/actin. Time-resolved FRET assays demonstrated that PKA phosphorylation reduces cMyBP-C binding to myosin and actin, and identified unique binding alterations caused by hypertrophic cardiomyopathy mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: